Plus   Neg

Haemonetics Boosts FY20 Adj. EPS Outlook - Quick Facts

While reporting financial results for the third quarter on Tuesday, healthcare company Haemonetics Corp. (HAE) again raised its adjusted earnings guidance for the full-year 2020, while reaffirming annual revenue growth outlook.

For fiscal 2020, the company raised its adjusted earnings guidance to a range of $3.30 to $3.40 per share from the prior forecast range of $3.10 to $3.20 per share, while continuing to project annual revenue growth of 3 to 5 percent and organic revenue growth of 6 to 8 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $3.18 per share on revenue growth of 3.8 percent to $1.0 billion for the year. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT